Year: 2022
Type: review
Abstract: Pirfenidone (PFD) slows the progression of idiopathic pulmonary fibrosis (IPF) by inhibiting the exaggerated fibrotic response and possibly through additional mechanisms, such as anti-inflammatory effects. PFD has also been evaluated in other fibrosing lung diseases. Myocardial fibrosis is a common feature of several heart diseases and the progressive deposition of extracellular matrix due to a persistent injury to cardiomyocytes may trigger a vicious cycle that leads to persistent structural and functional alterations of the myocardium. No primarily antifibrotic medications are used to treat patients with heart failure. There is some evidence that PFD has antifibrotic actions in various animal models of cardiac disease and a phase II trial on patients with heart failure and preserved ejection fraction has yielded positive results. This review summarises the evidence about the possible mechanisms of IPF and modulation by PFD, the main results about IPF or non-IPF interstitial pneumonias and also data about PFD as a potential protective cardiac drug.
Source: Cardiac failure review
DOI: 10.15420/cfr.2021.30
Institutions: Scuola Superiore Sant'Anna, Fondazione Toscana Gabriele Monasterio, Hospital Universitari Germans Trias i Pujol, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Universitat Autònoma de Barcelona, Instituto de Salud Carlos III, Centro de Investigación en Red en Enfermedades Cardiovasculares, Centro de Investigación Biomédica en Red
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,146
OpenAlex ID: W4223999663